Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

The use of novel B-cell receptor signaling inhibitors results in high response rates and long progression-free survival in patients with indolent B-cell malignancies, such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinemia. Ibrutinib, the fir...

Descripción completa

Detalles Bibliográficos
Autores principales: de Weerdt, Iris, Koopmans, Suzanne M., Kater, Arnon P., van Gelder, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622847/
https://www.ncbi.nlm.nih.gov/pubmed/28775119
http://dx.doi.org/10.3324/haematol.2017.164103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622847/
https://www.ncbi.nlm.nih.gov/pubmed/28775119
http://dx.doi.org/10.3324/haematol.2017.164103

Ejemplares similares